Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?

Abstract:

:The aim of this review is to provide a rationale for evaluating thiazolidinediones (TZDs) as putative treatments for cognitive deficits in individuals with mood disorders. A MedLine search of all English-language articles published between January 1966 and August 2006 was conducted. The search terms were: the non-proprietary names of TZDs (e.g., rosiglitazone and pioglitazone), peroxisome proliferator-activated receptor, cognition, neuroprotection, inflammation, oxidative stress, cellular metabolism and excitotoxicity cross-referenced with the individual names of mood (e.g., major depressive disorder and bipolar disorder) and dementing disorders (e.g., Alzheimer's disease) as defined in the Diagnostic and Statistical Manual of Mental Disorders third edition, revised/fourth edition, text revision (DSM-III-R/IV-TR). The search was augmented with a manual review of article reference lists. Articles selected for review were based on adequacy of sample size, the use of standardized experimental procedures, validated assessment measures and overall manuscript quality. Contemporary pathophysiologic models of mood disorders emphasize alterations in neuronal plasticity, metabolism and cytoarchitecture with associated regional abnormalities in neuronal (and glial) density and morphology. These abnormalities are hypothesized to subserve cognitive deficits and other clinical features of mood disorders. TZDs may attenuate, abrogate and/or reverse the neurotoxic effects of depressive illness by means of disparate mechanisms, notably insulin signaling, anti-inflammation, glucocorticoid activity and cellular metabolism. Extant data provide the basis for formulating a hypothesis that TZDs may be salutary for cognitive deficits and several aspects of somatic health (e.g., cardiovascular disease) associated with mood disorders.

authors

McIntyre RS,Soczynska JK,Woldeyohannes HO,Lewis GF,Leiter LA,MacQueen GM,Miranda A,Fulgosi D,Konarski JZ,Kennedy SH

doi

10.1517/14656566.8.11.1615

subject

Has Abstract

pub_date

2007-08-01 00:00:00

pages

1615-28

issue

11

eissn

1465-6566

issn

1744-7666

journal_volume

8

pub_type

杂志文章,评审
  • Sibutramine: current status as an anti-obesity drug and its future perspectives.

    abstract:BACKGROUND:Obesity has become a global epidemic with recent estimates of > 400 million obese adults. Despite this, there are few safe and effective pharmacological interventions for obesity. Sibutramine is a weight loss agent, for use as an adjuvant to a comprehensive program of calorie restriction, exercise and behavi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.12.2161

    authors: Sharma B,Henderson DC

    更新日期:2008-08-01 00:00:00

  • Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.

    abstract:INTRODUCTION:Irritable bowel syndrome (IBS) treatment is challenging physicians because of its multifactorial physiopathology. In particular, abdominal pain and diarrhea management lack one unique effective pharmacological remedy. Opioid receptors, present in the central nervous system (CNS) and the enteric nervous sys...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1182982

    authors: Scarpellini E,Laterza L,Ianiro G,Tack J,Abenavoli L,Gasbarrini A

    更新日期:2016-07-01 00:00:00

  • Transdermal oxybutynin: a new treatment for overactive bladder.

    abstract::Overactive bladder has been successfully treated with oral anticholinergic drugs such as oxybutynin chloride. Although oral oxybutynin has been effective in controlling urinary urge incontinence and in decreasing incontinence episodes, adverse events, particularly dry mouth, often cause patients to discontinue oral th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.12.2315

    authors: Davila GW

    更新日期:2003-12-01 00:00:00

  • Therapeutic options for HIV-associated lymphomas.

    abstract:IMPORTANCE OF THE FIELD:The clinical features and natural history of HIV-associated lymphomas differ greatly from those observed in the general population. The failure to improve outcomes with treatment intensification indicates the need for the introduction of new therapeutic options. AREAS COVERED IN THIS REVIEW:Thi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.502528

    authors: Spina M,Gloghini A,Tirelli U,Carbone A

    更新日期:2010-10-01 00:00:00

  • A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.

    abstract:INTRODUCTION:Psoriasis is a chronic, inflammatory disease afflicting 2% of the US population; it results in significant morbidity. The annual healthcare costs related to psoriasis are an estimated $11.3 billion and, with an expanding biologic market, an updated costs analysis is needed. AREAS COVERED:Current treatment...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.590475

    authors: Staidle JP,Dabade TS,Feldman SR

    更新日期:2011-09-01 00:00:00

  • Delaying surgery with chemotherapy for osteosarcoma of the extremities.

    abstract::Osteosarcoma is the most frequent primary cancer of bone. When treated by surgery alone, it is almost invariably followed by metastatic dissemination and death. This dismal prognosis can be improved dramatically by including chemotherapy in an interdisciplinary regimen. Today, two-thirds of patients with localised ext...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.6.1243

    authors: Bielack SS,Machatschek JN,Flege S,Jürgens H

    更新日期:2004-06-01 00:00:00

  • Etravirine for the treatment of HIV/AIDS.

    abstract:INTRODUCTION:Etravirine (TMC125) is an orally administered second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved in treatment-experienced patients as addition to an optimized background therapy (OBT). AREAS COVERED:A Medline search was conducted of Phase II - IV clinical trials, as ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.787411

    authors: Schrijvers R

    更新日期:2013-06-01 00:00:00

  • Drug interactions in the management of HIV infection.

    abstract::The availability of antiretroviral therapy has significantly reduced the morbidity and mortality of HIV infection. In addition, improved treatment of opportunistic infections and comorbidities common to patients with HIV is further prolonging the lives of patients. Improvement in the treatment of HIV has led to a sign...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.2.233

    authors: Robertson SM,Penzak SR,Pau AK

    更新日期:2005-02-01 00:00:00

  • On the front line: first choice pharmacotherapeutics for chronic lymphocytic leukemia.

    abstract:INTRODUCTION:Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with a highly variable clinical course. Frontline treatments include cytotoxic chemotherapies, immunotherapies, and small molecule inhibitors. Clinical and molecular factors guide treatment initiation and selection. Over the last decade,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1524874

    authors: Samples LS,Graf SA

    更新日期:2018-10-01 00:00:00

  • Osteoporosis in older persons: current pharmacotherapy and future directions.

    abstract:INTRODUCTION:Osteopororic fractures are highly prevalent in older persons having catastrophic consequences in their quality of life and increasing disability and mortality in this population. The mechanisms of osteoporosis in older persons are unique in terms of cellular changes and response to osteoporosis treatment. ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.822861

    authors: Duque G

    更新日期:2013-10-01 00:00:00

  • The use of alpha-adrenoceptor antagonists in lower urinary tract disease.

    abstract::alpha-adrenoceptor antagonists have traditionally been used in the treatment of hypertension but in recent years they have become increasingly common in the treatment of benign prostatic enlargement (BPE), where they reduce the 'dynamic' component of bladder outlet obstruction and appear to have additional actions to ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.2.167

    authors: Chess-Williams R

    更新日期:2002-02-01 00:00:00

  • Apomorphine in the treatment of Parkinson disease and other movement disorders.

    abstract:BACKGROUND:Apomorphine, a medication that has been studied intensively over the years, is available in the US as intermittent subcutaneous injections for treatment of 'off' motor states in Parkinson disease. OBJECTIVE:The clinical literature is summarized with particular focus on randomized controlled studies of apomo...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560902828344

    authors: Gunzler SA

    更新日期:2009-04-01 00:00:00

  • Challenges and treatment options for rheumatoid arthritis during pregnancy.

    abstract:INTRODUCTION:Rheumatoid arthritis (RA) can spontaneously improve during pregnancy. However, a considerable proportion of patients can experience a flare and high disease activity has been associated with an increased risk of adverse pregnancy outcome. Thus, the treatment of RA in pregnant women should be selected takin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1197204

    authors: Gerosa M,Schioppo T,Meroni PL

    更新日期:2016-08-01 00:00:00

  • Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer.

    abstract::Actinic keratosis (AK) and basal cell carcinoma (BCC) are precancerous and cancerous skin lesions that should be treated especially when multiple or in cosmetically important areas. Apart from 5% 5-fluorouracil topical cream, which some feel is the gold standard topical treatment for AK, several invasive treatment mod...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.11.1743

    authors: Papadavid E,Stratigos AJ,Falagas ME

    更新日期:2007-08-01 00:00:00

  • The use of cephalosporins for gonorrhea: the impending problem of resistance.

    abstract::Gonorrhea remains an important clinical and public health problem throughout the world. Gonococcal infections have historically been diagnosed by Gram stain and culture but are increasingly diagnosed through nucleic acid tests, thereby eliminating the opportunity for antimicrobial susceptibility testing. Gonococcal in...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560902731993

    authors: Barry PM,Klausner JD

    更新日期:2009-03-01 00:00:00

  • G-CSF as prophylaxis of febrile neutropenia in SCLC.

    abstract:OBJECTIVES:In 1991, small cell lung cancer (SCLC) was reported as the first tumour type where colony stimulating factor (CSF) support was clinically effective. We reviewed 13 health services research studies that addressed CSF use as supportive care for SCLC. METHODS:Findings from American Society of Clinical Oncology...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.9.1273

    authors: Adams JR,Lyman GH,Djubegovic B,Feinglass J,Bennett CL

    更新日期:2002-09-01 00:00:00

  • Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.

    abstract:OBJECTIVE:To explore the treatment response, tolerability and safety of once-monthly paliperidone palmitate (PP1M) in non-acute patients switched from oral antipsychotics, stratified by time since diagnosis as recently diagnosed (≤3 years) or chronic patients (>3 years). RESEARCH DESIGN AND METHODS:Post hoc analysis o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究

    doi:10.1080/14656566.2016.1174692

    authors: Hargarter L,Bergmans P,Cherubin P,Keim S,Conca A,Serrano-Blanco A,Bitter I,Bilanakis N,Schreiner A

    更新日期:2016-06-01 00:00:00

  • Child cured of HIV: can this be repeated?

    abstract::Eradication of HIV infection is the most challenging research area in the HIV/AIDS field. Treatment of HIV infection with antiretrovirals halts viral replication but fails to eradicate infection because it does not eliminate latent viruses. Eradication has only been achieved in one exceptional case after bone marrow t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.2013.835396

    authors: Blanco J

    更新日期:2013-12-01 00:00:00

  • Erectile dysfunction, cardiovascular diseases and depression: interaction of therapy.

    abstract::Several studies have revealed the intimate associations between erectile dysfunction (ED), ischemic heart disease (IHD) and depression. Whether the physicians should also screen for the other two components when a patient presents with one component of this triad is still an important question to be answered. These th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903089326

    authors: El-Sakka AI,Shamloul R,Yassin AA

    更新日期:2009-09-01 00:00:00

  • Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?

    abstract:INTRODUCTION:Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication. However, beyond its antiplatelet and vasodilator properties, cilostazol seems to have significant effects on atherogenic dyslipidemia. AREAS COVERED:The effec...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.557359

    authors: Rizzo M,Corrado E,Patti AM,Rini GB,Mikhailidis DP

    更新日期:2011-03-01 00:00:00

  • An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis.

    abstract:INTRODUCTION:Moderate-to-severe AD burdens a large proportion of AD patients and may represent an inadequacy of treatment options available for resistant disease. AREAS COVERED:This review provides an overview of the therapies for moderate-to-severe AD in late-stage development and in the clinic, and focuses on barici...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,评审

    doi:10.1080/14656566.2020.1739268

    authors: Mendes JT,Balogh EA,Strowd LC,Feldman SR

    更新日期:2020-06-01 00:00:00

  • Photodynamic therapy using 5-aminolaevulinic acid for the treatment of dysplasia in Barrett's oesophagus.

    abstract:BACKGROUND:5-Aminolaevulinic acid (ALA) is the naturally occurring metabolic precursor of an endogenously formed photosensitiser, protoporphyrin IX. It is used topically to treat benign and malignant skin disorders by a process called photodynamic therapy (PDT). Recently, data are emerging on its systemic use in the tr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.5.851

    authors: Dunn J,Lovat L

    更新日期:2008-04-01 00:00:00

  • Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.

    abstract:BACKGROUND:Alzheimer's disease is thought to be caused by increased formations of neurotoxic amyloid beta (A beta) peptides, which give rise to the hallmark amyloid plaques. Therefore, pharmacological agents that reduce A beta formation may be of therapeutic benefit. OBJECTIVE:This paper reviews the pharmacology and c...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903044982

    authors: Henley DB,May PC,Dean RA,Siemers ER

    更新日期:2009-07-01 00:00:00

  • Platelet glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions: a pharmacological and clinical review.

    abstract::One of the most significant advances of the last decade has been the development of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors. A large series of randomised, controlled clinical trials of these agents have shown a significant reduction in ischaemic events, not only in acute coronary syndrome patients, but...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.2.335

    authors: Anne G,Gruberg L

    更新日期:2004-02-01 00:00:00

  • Iontophoretic transdermal fentanyl for the management of acute perioperative pain in hospitalized patients.

    abstract:INTRODUCTION:Intravenous (I.V.) morphine administered through a patient-controlled system currently represents the gold standard treatment for moderate to severe acute postoperative pain. To fix the limitations showed by the available I.V. patient-controlled analgesia (PCA) systems that may restrict its use in the clin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1146684

    authors: Fanelli A,Sorella MC,Chelly JE

    更新日期:2016-01-01 00:00:00

  • Pharmacotherapy options in pulmonary alveolar proteinosis.

    abstract:INTRODUCTION:Pulmonary alveolar proteinosis (PAP) is a heterogeneous group of rare diseases characterized by the abnormal production and impaired degradation of pulmonary surfactant as a result of malfunctioning of alveolar macrophages. This is due to the downstream dysregulation of the GM-CSF pathway, which can be cau...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1757650

    authors: Antoniu SA,Rajnoveanu R,Grigore M,Antohe I

    更新日期:2020-08-01 00:00:00

  • Bendamustine for treatment of chronic lymphocytic leukemia.

    abstract:INTRODUCTION:Chronic lymphocytic leukemia (CLL) often has an extended disease course. With a median age at diagnosis of 72 years, newer treatment options with less toxicity than standard nucleoside analogue-based regimens are needed. Historically, few therapy options are available once CLL has become refractory to nucl...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.693163

    authors: Chang JE,Kahl BS

    更新日期:2012-07-01 00:00:00

  • Long-term treatment in pediatric asthma: an update on chemical pharmacotherapy.

    abstract:INTRODUCTION:Asthma is the most common chronic disease in childhood, affecting approximately 10% of all children, and is the leading cause of hospitalization in developed countries. In this paper we aimed to review the evidence on chemical pharmacotherapy for long-term treatment of pediatric asthma, according to the la...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1317747

    authors: Vitale C,Maglio A,Pelaia C,Vatrella A

    更新日期:2017-05-01 00:00:00

  • Posaconazole: a new broad-spectrum antifungal agent.

    abstract::The rising incidence of invasive fungal infections and the emergence of broader fungal resistance have led to the need for novel antifungal agents. Posaconazole is a new member of the triazole class of antifungals. It is available as an oral suspension and has a favorable toxicity profile, has demonstrated clinical ef...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.8.1167

    authors: Kwon DS,Mylonakis E

    更新日期:2007-06-01 00:00:00

  • Lipid pharmacotherapy for treatment of atherosclerosis.

    abstract:INTRODUCTION:For more than two decades, lowering levels of low-density lipoprotein cholesterol has formed the cornerstone of management of patients with atherosclerotic cardiovascular disease. The substantial residual risk of clinical events in patients treated with statin therapy highlights the need to develop more ef...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.904287

    authors: Nicholls SJ,Pisaniello AD,Kataoka Y,Puri R

    更新日期:2014-06-01 00:00:00